Showing results (101-110 of 160) with videos related to
Sort By:
Pageof 16
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 7, 2011
Palliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysisHans-Jürgen Biersack, Holger Palmedo, Andrej Andris, et al.Plos One|September 10, 2016
The Impact of Diffusion-Weighted MRI on the Definition of Gross Tumor Volume in Radiotherapy of Non-Small-Cell Lung CancerJochen Fleckenstein, Michael Jelden, Stephanie Kremp, et al.Clinical Nuclear Medicine|May 23, 2012
Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate?Samer Ezziddin, Jonas Lohmar, Charlotte J Yong-Hing, et al.Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|September 13, 2025
Assessment of scintigraphic imaging with Terbium-161: A visual and quantitative analysisFlorian Rosar, Sven Petto, Sebastian Ganz, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 2, 2016
68Ga-DOTATOC PET/CT in Patients with Iodine- and 18F-FDG-Negative Differentiated Thyroid Carcinoma and Elevated Serum ThyroglobulinIna Binse, Thorsten D Poeppel, Marcus Ruhlmann, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2014
Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotateSamer Ezziddin, Mared Attassi, Charlotte J Yong-Hing, et al.Cancers|March 11, 2023
Detection Efficacy of 68Ga-PSMA-11 PET/CT in Biochemical Recurrence of Prostate Cancer with Very Low PSA Levels: A 7-Year, Two-Center "Real-World" ExperienceCaroline Burgard, Manuela A Hoffmann, Madita Frei, et al.EJNMMI Radiopharmacy and Chemistry|December 11, 2024
Development of a homotrimeric PSMA radioligand based on the NOTI chelating platformSebastian Martin, Moritz-Valentin Schreck, Tobias Stemler, et al.Theranostics|September 18, 2025
Pilot experience of [161Tb]Tb-PSMA-617 RLT in mCRPC patients after conventional PSMA RLT within a prospective registryFlorian Rosar, Caroline Burgard, Christine Petrescu, et al.Clinical Nuclear Medicine|March 2, 2022
89Zr-PSMA-617 PET/CT May Reveal Local Recurrence of Prostate Cancer Unidentified by 68Ga-PSMA-11 PET/CTFlorian Rosar, Mark Bartholomä, Stephan Maus, et al.Pageof 16